Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...
(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...
BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...
The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...
It was led by venture capital firm ARCH Venture Partners, with other prominent biotech investors participating, including OrbiMed, Fairmount, Fidelity Management, and Sanofi Ventures. Mirador ...
Almost five years after leaving Spark Therapeutics, Dr. Katherine High is back at the helm of a gene therapy company with ...
In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...
RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...
Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...
RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...
Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback